Abstract 454P
Background
Deep Vein Thrombosis and Pulmonary Embolism have been associated with significant morbidity and mortality worldwide. The risk of developing lower limb Deep Vein Thrombosis may be associated with cancer-related, patient, and treatment-related risk factors. Although the association between cancer and venous thromboembolism is well known, there is a paucity of information in Asian patients with respect to cancer-associated thrombosis.
Methods
This prospective, observational study was conducted at Artemis Hospital, Gurugram, a Tertiary Health Care Center in (Northern) India. We identified all the consecutive patients with histologically confirmed newly diagnosed Stage III/IV solid tissue malignancies between June 2021 and May 2022. Duplex Doppler Ultrasound of the bilateral lower limb was performed to determine the prevalence of Deep Vein Thrombosis. Data on clinical and tumor characteristics were collected and compared among patients with and without lower limb Deep Vein Thrombosis.
Results
A total of 100 patients were enrolled in the study. On Duplex Doppler venous ultrasound, the prevalence of lower limb deep vein thrombosis was 14%. An adjusted multivariable regression analysis showed that advanced stage (p=0.008), leukocytosis(p=0.042), OR[1.0],95% CI(1.00,1.2), deranged coagulation profile (Raised APTT, PT)(p=0.01),OR [1.74], 95%CI(1.14,2.679) hypercholesterolemia(p=0.007), OR[1.02], 95%CI (1.004,1.05) were independent predictors of Deep vein Thrombosis. The highest prevalence of venous thromboembolism was for pancreatic (2%) and lung cancer (2%).
Conclusions
Cancer-related thrombosis has to bear in treatment outcomes as well as morbidity and mortality. Routine lower-extremity Venous Doppler Ultrasonographic screening is useful for early detection and management at an initial evaluation of stage III/IV solid malignancies. There is a paucity of data on Indian patients. This is the first study conducted in the Indian subcontinent that has identified high-risk factors and prevalence of venous thromboembolism. Such study design will help us in formulating national-level guidelines for prophylaxis of cancer-associated thrombosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
420P - Predictive factors of post-operative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
Presenter: Chito Cabiling
Session: Poster viewing 06
421P - The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Presenter: Deniz Can Guven
Session: Poster viewing 06
422P - Molecular mechanism in prostate cancer with TP53 mutation
Presenter: Bin Hu
Session: Poster viewing 06
423P - Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
Presenter: David Lee
Session: Poster viewing 06
424P - The Storm: Paraneoplastic leucomoid reaction - A bad prognostic factor
Presenter: Abdullah Al Mamun Khan
Session: Poster viewing 06
425P - Preliminary study: Assessment of public trust in traditional medicine and medical treatment in cancer patients in Indonesia - Study validity and reliability of the Universitas Sebelas Maret Trust and readiness assessment for cancer patients (UNS – TRAfCP35) questionnaire
Presenter: Widyanti Soewoto
Session: Poster viewing 06
426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
Presenter: Alexey Rumyantsev
Session: Poster viewing 06
427P - Oncology combination therapies in Asia-Pacific markets: What are the current access challenges?
Presenter: Gayathri Kumar
Session: Poster viewing 06
428P - Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Presenter: PRASHANT SIROHIYA
Session: Poster viewing 06